WO2005054270A3 - Identification and design of sirna molecules - Google Patents

Identification and design of sirna molecules Download PDF

Info

Publication number
WO2005054270A3
WO2005054270A3 PCT/GB2004/005015 GB2004005015W WO2005054270A3 WO 2005054270 A3 WO2005054270 A3 WO 2005054270A3 GB 2004005015 W GB2004005015 W GB 2004005015W WO 2005054270 A3 WO2005054270 A3 WO 2005054270A3
Authority
WO
WIPO (PCT)
Prior art keywords
identification
target rna
molecule
design
target
Prior art date
Application number
PCT/GB2004/005015
Other languages
French (fr)
Other versions
WO2005054270A2 (en
Inventor
Muhammad Sohail
Original Assignee
Isis Innovation
Muhammad Sohail
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation, Muhammad Sohail filed Critical Isis Innovation
Publication of WO2005054270A2 publication Critical patent/WO2005054270A2/en
Publication of WO2005054270A3 publication Critical patent/WO2005054270A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Abstract

A method for the identification of a RNA molecule that binds selectively to a target RNA molecule and is therefore capable of being used as a siRNA ,molecule,, comprises: (i) contacting an array of immobilised polynucleotide molecules with a detectably-labelled target RNA; (ii) monitoring the extent to which the target RNA hybridises to the array; and (iii) identifying the sequence of an immobillsed RNA molecule that hybridises to the target, wherein, either prior to or at the same time as step (i), a further polynucleotide is hybridised to the target RNA, and the extent of hybridisation in step (ii) is compared to a control lacking the further polynucleotide.
PCT/GB2004/005015 2003-11-28 2004-11-29 Identification and design of sirna molecules WO2005054270A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0327726.6 2003-11-28
GB0327726A GB0327726D0 (en) 2003-11-28 2003-11-28 Method

Publications (2)

Publication Number Publication Date
WO2005054270A2 WO2005054270A2 (en) 2005-06-16
WO2005054270A3 true WO2005054270A3 (en) 2006-03-16

Family

ID=29798022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/005015 WO2005054270A2 (en) 2003-11-28 2004-11-29 Identification and design of sirna molecules

Country Status (2)

Country Link
GB (1) GB0327726D0 (en)
WO (1) WO2005054270A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20110046067A1 (en) * 2007-06-22 2011-02-24 Intradigm Corporation COMPOSITIONS COMPRISING HUMAN EGFR-siRNA AND METHODS OF USE
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
EP2167689B1 (en) 2007-07-06 2012-10-31 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2009071722A1 (en) * 2007-12-07 2009-06-11 Newbiotechnic, S.A. METHODS AND KITS FOR PREPARING GENE LIBRARIES OF SPECIFIC siRNAs OF A TRANSCRIPTOME BY MEANS OF CONVERGENT TRANSCRIPTION
EP3208337A1 (en) * 2008-09-02 2017-08-23 Alnylam Pharmaceuticals, Inc. Compositions for combined inhibition of mutant egfr and il-6 expression
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP2382328A2 (en) 2009-01-09 2011-11-02 The Regents of the University of Michigan Recurrent gene fusions in cancer
CN103547288B (en) 2011-01-10 2016-03-16 密执安大学评议会 Stem cell factor inhibitor
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
WO2012145582A2 (en) * 2011-04-22 2012-10-26 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibitions of egfr by double-stranded rna
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
PT2729173T (en) 2011-07-06 2016-09-22 Sykehuset Sorlandet Hf Egfr targeted therapy
JP2016507493A (en) 2012-12-21 2016-03-10 スィーケフス ソールラン ホーエフ EGFR targeted treatment of neuropathy and pain
US20160083424A1 (en) 2013-04-26 2016-03-24 Oslo Universitetssykehus Hf Compositions and methods for targeting antigen-presenting cells
MA45349A (en) * 2016-04-01 2019-02-06 Avidity Biosciences Llc EGFR NUCLEIC ACIDS AND THEIR USES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186909A1 (en) * 1997-01-27 2003-10-02 Ribozyme Pharmaceuticals, Inc. Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186909A1 (en) * 1997-01-27 2003-10-02 Ribozyme Pharmaceuticals, Inc. Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEALE G ET AL: "GENE SILENCING NUCLEIC ACIDS DESIGNED BY SCANNING ARRAYS: ANTI-EGFR ACTIVITY OF SIRNA, RIBOZYME AND DNA ENZYMES TARGETING A SINGLE HYBRIDIZATION-ACCESSIBLE REGION USING THE SAME DELIVERY SYSTEM", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, vol. 11, no. 7, August 2003 (2003-08-01), pages 449 - 456, XP009034373, ISSN: 1061-186X *
BOHULA E A ET AL: "The Efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 278, no. 18, 2 May 2003 (2003-05-02), pages 15991 - 15997, XP002304220, ISSN: 0021-9258 *
TUSCHL T ET AL: "Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy", MOLECULAR INTERVENTIONS, vol. 2, 2002, pages 158 - 165, XP002294002 *

Also Published As

Publication number Publication date
GB0327726D0 (en) 2003-12-31
WO2005054270A2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2005054270A3 (en) Identification and design of sirna molecules
WO2003062462A3 (en) Method for isolating nucleic acids and protein from a single sample
IS8314A (en) Determination of polynucleotide
WO2010026488A3 (en) Methods and kits for nucleic acid sequencing
WO2007106509A3 (en) Methods and means for nucleic acid sequencing
WO2002101022A3 (en) Method for rapid amplification of dna
EP1845160A4 (en) Method for amplification of nucleotide sequence
WO2004072238A3 (en) Terminal-phosphate-labeled nucleotides with new linkers
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
WO2005021794A3 (en) Ola-based methods for the detection of target nucleic acid sequences
WO2005044836A3 (en) Macromolecular nucleotide compounds and methods for using the same
WO2007035684A3 (en) Method for quantitative detection of short rna molecules
WO2007004057A3 (en) Chromosome conformation capture-on-chip (4c) assay
WO2003064691A3 (en) Methods and means for amplifying nucleic acid
WO2007086935A8 (en) Methods of amplifying and sequencing nucleic acids
EP1484416A3 (en) Method of identifying and quantifying specific fungi and bacteria
WO2009102878A3 (en) Method for archiving and clonal expansion
WO2005021786A8 (en) A method of sequencing nucleic acids by ligation of labelled oligonucleotides
WO2005030984A3 (en) Method for small volume nucleic acid synthesis
WO2010036359A3 (en) Methods of polymerase activity assay
WO2004104229A3 (en) Internal control nucleic acid molecule for nucleic acid amplification systems
WO2002040126A3 (en) Methods for identifying nucleotides at defined positions in target nucleic acids using fluorescence polarization
AU2003288105A1 (en) Microarray-based method for amplifying and detecting nucleic acids during a continuous process
WO2007035685A3 (en) Compositions and methods for purifying nucleic acids
WO2002059353A3 (en) Two-step amplification using a program primer followed by specific primers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase